Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | F12 | P00748 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258487 | 0.88 | RAB9A (0.70) | NPC1RAB9APOLBMAOBF12 | |
| SCHEMBL5867051 | 0.82 | F12 (0.72) | NPC1RAB9AMAOBF12MEN1 | |
| SCHEMBL23258256 | 0.79 | MMP2 (0.57) | NPC1RAB9APOLBMAOBF12 | |
| SCHEMBL6239637 | 0.79 | POLB (0.58) | NPC1RAB9APOLBMAOBF12 | |
| SCHEMBL23258437 | 0.79 | MAOB (0.56) | NPC1RAB9APOLBMAOBF12 | |
| SCHEMBL4001852 | 0.79 | POLB (0.69) | NPC1RAB9APOLBMAOBF12 | |
| SCHEMBL23258446 | 0.78 | POLB (0.59) | NPC1RAB9APOLBMAOBF12 | |
| Hydrochloric Acid SCHEMBL7803214 | 0.77 | POLB (0.68) | NPC1RAB9APOLBMAOBF12 | |
| SCHEMBL23258329 | 0.77 | SMN1; SMN2 (0.61) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL2102040 | 0.76 | NPC1 (0.56) | NPC1RAB9APOLBMAOBF12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115007-A1 | STREPTOCOCCUS MUTANS GLUCOSYL TRANSFERASE INHIBITORS FOR DENTAL CARIES THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115007-A1 | STREPTOCOCCUS MUTANS GLUCOSYL TRANSFERASE INHIBITORS FOR DENTAL CARIES THERAPY | UGGT1, UGCG, GLA | NPC1 649/4885RAB9A 1534/4885POLB 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.